Clearmind Medicine Shares Are Trading Higher After the Company Announced Advancement in Its Proprietary MEAI- Based Binge Behavior Regulator Program Through the Granting of Patent Approval in Hong Kong by the Hong Kong Patent Office.
Clearmind Medicine Shares Are Trading Higher After the Company Announced Advancement in Its Proprietary MEAI- Based Binge Behavior Regulator Program Through the Granting of Patent Approval in Hong Kong by the Hong Kong Patent Office.
Clearmind Medicine股票價格上漲，公司宣佈其專有的MEAI基礎暴食行爲調節器計劃取得香港專利局批准。
Clearmind Medicine Shares Are Trading Higher After the Company Announced Advancement in Its Proprietary MEAI- Based Binge Behavior Regulator Program Through the Granting of Patent Approval in Hong Kong by the Hong Kong Patent Office.
Clearmind Medicine股票價格上漲，公司宣佈其專有的MEAI基礎暴食行爲調節器計劃取得香港專利局批准。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。